Does psilocybin work for depression that other treatments have not fixed?
Yes, at least in this trial. Adults who took a single 25 mg dose of psilocybin with psychological support scored 10.41 points lower on a standard depression rating scale at week 3 than adults who took a placebo. The gap was still there at week 6.
What makes this study different is where it happened. The trial, called PsiDeR, ran inside a National Health Service clinic in England, not a private research center. Sixty adults took part. All of them had major depressive disorder that had already failed to respond to at least two antidepressants, or to at least one antidepressant plus at least one course of psychotherapy. In plain terms, these were people for whom the usual options had already been tried and had not worked.
Everyone got the same package of care around the dose: preparation sessions before, support during the dosing day, and integration sessions afterward to make sense of the experience. Half the group got 25 mg of psilocybin. Half got a placebo. Neither the participants nor the staff knew who got which, which is what “double-blind” means.
What the data show
The main number is the difference in scores on the Montgomery-Asberg Depression Rating Scale, or MADRS, a scale where a higher score means more severe depression. At week 3, the psilocybin group sat 10.41 points below the placebo group after the researchers adjusted their analysis.
That gap comes with a range around it, running from 14.86 points to 5.95 points. Read that as certainty language: it is very likely that the true benefit is somewhere between a large 14.86-point drop and a still meaningful 5.95-point drop, and the whole range favors psilocybin. Nothing in that range points back toward placebo being better.
The researchers also reported an effect size of 1.70 (Cohen’s d = -1.70). Effect size is a way of asking how big a difference is compared with how much people naturally vary. The benefit was sustained at week 6, the end of follow-up.
Retention was close to perfect. Of the 60 people randomized, 59 completed the MADRS at every single follow-up visit.
Dr. Kumar’s Take
I want to be careful here, because the effect size is the kind of number that makes headlines, and the study design does not support headline treatment.
This was a feasibility trial. Its stated primary goals were recruitment, retention, and getting a decent estimate of how much depression scores vary, all of which are the plumbing you need before running a real confirmatory trial. The depression difference is the number everyone will quote, but it was not the question the trial was built to answer. The authors say so themselves, and their conclusion is that these findings support a future confirmatory trial, not that psilocybin is ready for the clinic.
What I find encouraging is the setting. A lot of psychedelic research has happened in specialized centers with highly selected volunteers. Running this inside an NHS clinic, with 59 of 60 people showing up for every follow-up visit, tells me the logistics are workable in ordinary public healthcare. That is not a small thing. Plenty of promising treatments die because they cannot survive contact with a normal clinic schedule.
Safety, limits, and caveats
Side effects were more common with psilocybin, but none were serious. Across the whole trial there were 164 nonserious adverse events in the psilocybin arm and 123 in the placebo arm. Those are counts of events, not counts of people, so a single participant could account for several.
The limits are real. Sixty people is a small sample. Follow-up stopped at 6 weeks, so nobody knows what these depression scores look like at six months or a year. It ran at a single site, which means the results reflect one clinic’s staff and one clinic’s patient population.
Practical takeaways
- Psilocybin is not an available prescription treatment for depression in most places, so treat this study as a signal about where research is heading, not as a reason to seek out mushrooms on your own.
- The psilocybin in this trial never came alone. It was paired with preparation, in-person support during dosing, and integration sessions afterward, and that whole package is what was tested.
- If you have depression that has not responded to two or more treatments, ask your psychiatrist about clinical trials you might qualify for, since that is currently the legitimate route to access.
- Keep taking what you have been prescribed. Nothing in a 60-person, 6-week feasibility trial justifies stopping a treatment that is helping you.
Related studies and research
- Single-dose psilocybin vs placebo: first double-blind depression trial
- Single-dose psilocybin shows rapid, sustained antidepressant effects
- Mindfulness-based cognitive therapy for major depression in students
- SAMe augmentation in major depressive disorder
FAQs
What does “treatment-resistant depression” actually mean?
In this trial it had a specific definition. Participants had to meet DSM-5 criteria for major depressive disorder and have had an inadequate response to at least two antidepressant treatments, or to at least one antidepressant plus at least one course of psychotherapy. That matters because “treatment-resistant” gets used loosely in conversation, and the threshold a study uses changes who ends up in the room. A stricter definition means a harder-to-treat group, which usually makes any benefit more impressive and harder to achieve.
Why does it matter that this was a “feasibility” trial?
A feasibility trial asks whether a bigger study can realistically be run. Here the stated primary outcomes were recruitment, retention, and estimating how much MADRS scores vary between people. That last one sounds dull but it is what statisticians need to work out how many participants a confirmatory trial requires. So the honest reading is that this study cleared the runway rather than landing the plane. The depression result is a bonus finding that helps justify the next, larger trial.
Is a 10-point difference on a depression scale a lot?
It is a substantial shift, and the effect size of 1.70 the researchers reported is very large by conventional standards. But scale points and real life are not the same thing. A large average difference can hide the fact that some people improved dramatically and others barely moved, and averages in small trials bounce around more than averages in large ones. This is exactly why the authors are calling for a confirmatory trial rather than declaring the question settled.
Bottom line
A single 25 mg dose of psilocybin, given with psychological support inside an NHS clinic, put depression scores 10.41 points below placebo at week 3 in 60 adults whose depression had already resisted at least two treatments, and that gap held at week 6. Side effects were more common with psilocybin but none were serious. The design was a feasibility trial at one site with 6 weeks of follow-up, so the right conclusion is the one the authors reached: this is strong enough to justify a larger confirmatory trial, not strong enough to change practice.
